Altimmune Stock Performance
| ALT Stock | USD 8.25 0.07 0.86% |
On a scale of 0 to 100, Altimmune holds a performance score of 4. The firm shows a Beta (market volatility) of 0.98, which signifies possible diversification benefits within a given portfolio. Altimmune returns are very sensitive to returns on the market. As the market goes up or down, Altimmune is expected to follow. Please check Altimmune's skewness, and the relationship between the value at risk and day median price , to make a quick decision on whether Altimmune's price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Altimmune are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent essential indicators, Altimmune unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.86 | Five Day Return (8.94) | Year To Date Return (21.58) | Ten Year Return (93.81) | All Time Return (93.81) |
Last Split Factor 1:30 | Dividend Date 2018-09-14 | Ex Dividend Date 2017-01-20 | Last Split Date 2018-09-14 |
1 | Supreme Court dropsFacebooks appeal of investor suit in Cambridge Analytica scandal | 11/22/2024 |
2 | Augmented Reality Software Development Kit Market Valuation is Set to Skyrocket to US 26.14 Billion By 2032 Astute Analytica | 11/27/2024 |
3 | Global Chronic Ocular Pain Market Poised to Reach 12.44 Billion by 2032, Growing at a CAGR of 6.58 percent Astute Analytica | 12/02/2024 |
4 | Saudi Arabia Artisanal Cakes Market Set to Exceed 2 Billion by 2032, Growing at a CAGR of 8.8 percent Astute Analytica | 12/05/2024 |
5 | Global Event and Exhibition Market to Reach US 58.96 Billion by 2032, Growing at a CAGR of 3.30 percent Astute Analytica | 12/06/2024 |
6 | Meta shareholders seek sanctions for Sandberg, Zients for deleting Cambridge Analytica emails | 12/09/2024 |
7 | Japan Mobile Mapping Market to Hit Valuation of US 65.0 Billion By 2033 Astute Analytica | 12/10/2024 |
8 | Altimmune reports positive trial results for liver disease drug | 12/12/2024 |
9 | Altimmunes SWOT analysis pemvidutides potential reshapes obesity stock outlook | 12/16/2024 |
10 | Facebook-parent Meta settles with Australias privacy watchdog over Cambridge Analytica lawsuit | 12/17/2024 |
11 | Saudi Arabia Light Commercial Vehicle Market to Attain Valuation of US 8,836.27 Million By 2032 Astute Analytica | 12/19/2024 |
12 | Altimmune Gains on Nasdaq Biotechnology Index Inclusion | 12/20/2024 |
| Begin Period Cash Flow | 111.1 M | |
| Free Cash Flow | -75.9 M |
Altimmune |
Altimmune Relative Risk vs. Return Landscape
If you would invest 720.00 in Altimmune on September 23, 2024 and sell it today you would earn a total of 105.00 from holding Altimmune or generate 14.58% return on investment over 90 days. Altimmune is generating 0.3574% of daily returns assuming volatility of 5.6507% on return distribution over 90 days investment horizon. In other words, 50% of stocks are less volatile than Altimmune, and above 93% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Altimmune Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Altimmune's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Altimmune, and traders can use it to determine the average amount a Altimmune's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0633
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ALT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.65 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.36 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Altimmune is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Altimmune by adding it to a well-diversified portfolio.
Altimmune Fundamentals Growth
Altimmune Stock prices reflect investors' perceptions of the future prospects and financial health of Altimmune, and Altimmune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Altimmune Stock performance.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 450.24 M | ||||
| Shares Outstanding | 71.12 M | ||||
| Price To Earning | (1.66) X | ||||
| Price To Book | 4.41 X | ||||
| Price To Sales | 11,284 X | ||||
| Revenue | 426 K | ||||
| Gross Profit | (70.52 M) | ||||
| EBITDA | (87.94 M) | ||||
| Net Income | (88.45 M) | ||||
| Cash And Equivalents | 184.76 M | ||||
| Cash Per Share | 3.81 X | ||||
| Total Debt | 671 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.12 X | ||||
| Book Value Per Share | 1.88 X | ||||
| Cash Flow From Operations | (75.81 M) | ||||
| Earnings Per Share | (1.57) X | ||||
| Market Capitalization | 586.78 M | ||||
| Total Asset | 210.64 M | ||||
| Retained Earnings | (466.33 M) | ||||
| Working Capital | 197.48 M | ||||
| Current Asset | 13.9 M | ||||
| Current Liabilities | 10.49 M | ||||
About Altimmune Performance
Assessing Altimmune's fundamental ratios provides investors with valuable insights into Altimmune's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Altimmune is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 209.87 | 220.37 | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.48) | (0.51) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.46) | (0.48) |
Things to note about Altimmune performance evaluation
Checking the ongoing alerts about Altimmune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Altimmune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Altimmune had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 426 K. Reported Net Loss for the year was (88.45 M) with loss before taxes, overhead, and interest of (70.52 M). | |
| Altimmune has about 184.76 M in cash with (75.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81. | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Altimmune Gains on Nasdaq Biotechnology Index Inclusion |
- Analyzing Altimmune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Altimmune's stock is overvalued or undervalued compared to its peers.
- Examining Altimmune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Altimmune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Altimmune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Altimmune's stock. These opinions can provide insight into Altimmune's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.